<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170310</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HNP006</org_study_id>
    <nct_id>NCT03170310</nct_id>
  </id_info>
  <brief_title>Apatinib Treatment for Advanced Esophagus Cancer</brief_title>
  <official_title>Apatinib Treatment for Advanced Esophagus Cancer ,One-armed，Exploratory，Openting , Clinical Trail.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subject ever received a standard chemotherapy solution progression or recurrence or can't
      tolerate chemotherapy with advanced esophageal squamous carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2017</start_date>
  <completion_date type="Anticipated">September 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time subject into the group to tumor objective progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Time subject into the group to die.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Esophagus Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age: 18 to 75 years old, men and women;

          -  2. After histopathological and immunohistochemical examination diagnosis of esophageal
             squamous cell carcinomas. At least one measurable lesion after the treatment (the
             length to diameter of CT scan≥10 mm , accord with the requirement of RESCIST 1.1);the
             lesions of whom had not received radiotherapy.

          -  3. Advanced esophageal squamous cell carcinoma without molecular targeted drug
             therapy;

          -  4. ECOG PS:0-1;

          -  5. Life expectancy≥12 weeks;

          -  6. Patients who have disease progressed or relapsed after standard chemotherapy, or
             who have been unable to tolerate chemotherapy;

          -  7. The main organs function properly, that is, meet the following criteria:

               1. blood routine examination: HB≥90 g / L; (without blood transfusion during 14
                  days) ANC≥1.5×109 /L; PLT≥80×109 / L;

               2. biochemical examination: ALB≥30g / L; (without infusion of albumin during 14
                  days) ALT and AST&lt;2ULN; TBIL≤1.5ULN; Plasma Cr≤1.5ULN;

          -  8. The results of the serum pregnancy test of women in childbearing age must be
             negative in the 7 days prior to treatment; all patients (both male and female) should
             take adequate barrier contraception within the entire treatment and 4 weeks after
             treatment.

          -  9. Subject should volunteer to join the study, sign the informed consent, have good
             compliance and cooperate with the follow-up;

          -  10. Investigator believe that subject who can benefit.

        Exclusion Criteria:

          -  1. In the past or at the same time with suffered from other malignancies;

          -  2. Pregnant or lactating women;

          -  3. Patients with high blood pressure and can't get a good control after
             antihypertensive drug therapy (systolic blood pressure&gt;150mmHg, diastolic blood
             pressure&gt;100mmHg); patients with grade Ⅱ or more myocardial ischemia or myocardial
             infarction, poorly controlled arrhythmia (including QTC interval≥450ms) and Ⅲ~Ⅳ grade
             cardiac insufficiency according to NYHA; cardiac color Doppler ultrasonography: LVEF
             &lt;50%;

          -  4. Unable to swallow, chronic diarrhea and intestinal obstruction, significantly
             affect the drug taking and absorption;

          -  5. With a clear risk of gastrointestinal bleeding (such as locally active ulcer
             lesions, fecal occult blood above + +), history of gastrointestinal bleeding within 6
             months, and unhealed wounds;

          -  6. Central nervous system metastasis has occurred;

          -  7. With abnormal coagulation function (PT&gt;16s, APTT&gt;43s, TT&gt;21s, Fbg&lt;2g/L), with
             bleeding tendency or receiving thrombolytic or anticoagulant therapy;

          -  8. With mental illness, or mental history of drug abuse;

          -  9. With anastomotic recurrence;

          -  10. Patients who have participated in other drug clinical trials in 4 weeks;

          -  11. Patients who have concomitant diseases that are seriously compromise the patient's
             safety or affect the patient to complete the study according to the researcher's
             judgment;

          -  12. Patients those researchers believe not suitable for the inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Liu</last_name>
    <phone>13783604602</phone>
    <email>yaya7207@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Liu, MD</last_name>
      <phone>+86-13783604602</phone>
      <email>Yaya7207@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

